Floatz logo

Semaglutide

Duchenne Muscular Dystrophy (DMD)

Vanderbilt University Medical Centerprotein_peptidePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

55 Active assets in the Duchenne Muscular Dystrophy (DMD) cohort.

Asset / SponsorPhaseRating
Viltolarsen
NS Pharma, Inc.
Phase 4BBB
Delandistrogene Moxeparvovec
Sarepta Therapeutics, Inc.
Phase 3BB
Golodirsen
Rare Disease Research, LLC
Phase 4BB
Aoc 1044
Avidity Biosciences, Inc.
Phase 3BB
Avi-4658
Sarepta Therapeutics, Inc.
Phase 3BB

View all 50 →

Same molecule, other indications

Semaglutide is also rated in:

metabolic diseaseDormant
A
Indicative ·
81 / 100
View asset →
type 2 diabetes mellitusDormant
BBB
Indicative ·
79 / 100
View asset →
polycystic ovary syndromeDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →